Recurrent Platinum-sensitive Ovarian Cancer
Conditions
Keywords
Ovarian Carcinoma, Bevacizumab, Gemcitabine, PLD, pegylated liposomal doxorubicin, Carboplatin, best therapeutic index, progression-free survival
Brief summary
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
Interventions
Sponsors
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
ARCAGY/ GINECO GROUP
Australia New Zealand Gynaecological Oncology Group
Scottish Gynaecological Cancer Study Group
AGO Research GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed diagnosis of epithelial ovarian carcinoma or fallopian tube carcinoma or primary peritoneal carcinoma 2. First disease recurrence \>6 months after first-line platinum-based chemotherapy 3. Patients with measurable or non-measurable disease (RECIST v1.1) or CA 125 assessable disease (GCIG criteria) or histological proven diagnosis of relapse 4. In case of cytoreductive surgery for recurrence, patients must be able to commence cytotoxic chemo-therapy within 8 weeks after cytoreductive surgery 5. ECOG PS 0-2 6. Absolute Neutrophil Count \>= 1.5 x 10\^9/L; Platelets \>= 100 x 10\^9/L; Hemoglobin \>= 9.5 g/dL 7. Patients not receiving anticoagulant medication who have an International Normalized Ratio \<= 1.5 and an Activated ProThrombin Time \<= 1.5 x ULN 8. Serum bilirubin \<= 2 x ULN; Serum transaminases \<= 2.5 x ULN (\<= 5 x ULN in the presence of liver metastasis) 9. Serum creatinine \< 1.6 mg/dL or creatinine clearance \>= 40 mL/min; Glomerular filtration rate \> 40 ml/min (estimates based on the Cockroft-Gault or Jelliffe formula); Urine dipstick for proteinuria \< 2+. If urine dipstick is \>= 2+, 24 hour urine collection must demonstrate \<= 1 g of protein in 24 hours 10. Normal blood pressure or adequately treated and controlled hypertension (either systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg)
Exclusion criteria
1. Ovarian tumors of low malignant potential 2. Malignancies other than ovarian cancer within 5 years prior to randomization 3. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period 4. Any previous radiotherapy to the abdomen or pelvis 5. Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab and its excipients, chinese hamster ovary cell products or other recombinant human or humanised antibodies 6. Current or recent chronic use of aspirin \> 325 mg/day 7. Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of Bevacizumab 8. History of VEGF therapy related abdominal fistula or gastrointestinal perforation 9. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease 10. Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure 11. Previous Cerebro-Vascular Accident , Transient Ischaemic Attack or Sub-Arachnoid Haemorrhage 12. Prior history of hypertensive crisis or hypertensive encephalopathy 13. Clinically significant disease, including: myocardial infarction or unstable angina within ≤ 6 months of randomization; New York Heart Association (NYHA) \>= grade 2 Congestive Heart Failure; poorly controlled cardiac arrhythmia despite medication; peripheral vascular disease grade \>= 3 14. LVEF defined by ECHO/MUGA below the institutional lower limit of normal 15. Significant traumatic injury during 4 weeks prior to randomization 16. Current brain metastases or spinal cord compression 17. History or evidence upon neurological examination of central nervous system disease 18. Non-healing wound, active ulcer or bone fracture 19. History or evidence of thrombotic or hemorrhagic disorders within 6 months prior to randomization 20. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic coagulation) 21. Fertile woman of childbearing potential not willing to use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) for the duration of the trial and at least 6 months afterwards 22. Pregnant or lactating women 23. Requirement of therapeutic anticoagulation using marcumar, warfarin or PTT-prolonging heparin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| investigator-determined progression-free survival | every 12 weeks until progression or up to 30 months (whichever occurs first) |
Secondary
| Measure | Time frame |
|---|---|
| biological progression-free survival by serum CA 125 | every 3 weeks until progression or up to 30 months (whichever occurs first) |
| Health related Quality of Life (QoL) | Baseline and then every 12 weeks until investigator-determined progresssion-free survival and thereafter at every visit for th 5-years follow-up or death (whichever occurs first) |
| Safety and Tolerability, i.e. type, frequency, severity and duration o adverse reactions | every 3 weeks, 30 months after start of treatment or if applicable 4 weeks after last dose of bevacizumab (whichever occurs later) |
| Overall Survival | every 3 weeks during treatment with bevacizumab, thereafter every 6 months; for up 30 months |
Countries
Australia, Austria, Belgium, France, Germany, United Kingdom
Outcome results
None listed